Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Fixed Dose Study of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

NCT00530114 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00530114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00530114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Fixed Dose Study of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
February 28, 2009
Enrollment
167 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, end stage renal disease, hyperphosphatemic, kidney disease